All In Biotech

Drug Trial Radar · NCT06659549

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

A Phase 2, Double-masked, Randomized, Multicenter, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of GAL-101, 2%, Ophthalmic Solution in Patients With Non-foveal Geographic Atrophy Secondary to Non-neovascular Age-related Macular Degeneration: eDREAM Study

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Jan 10, 2025

Primary completion

Mar 30, 2028

Study completion May 30, 2028

Sponsor

Lead sponsor
Galimedix Therapeutics IncIndustry
Sponsor type
Industry
First posted
Oct 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and details cannot be seen anymore. The purpose of the eDREAM study is to understand if GAL-101 can slow the growth of GA and prevent it from reaching the fovea. GAL-101 is given as eyedrops. eDREAM patients will administer study eyedrops every day. Patients will be assigned by chance (randomly) to receive either eye-drops that contain the new medication, GAL-101, or eyedrops without the active drug (Placebo). Neither patients nor doctors will know which treatment was assigned to each patient until the end of the study.

Conditions

  • Geographic Atrophy of the Macula

Interventions

  • GAL-101Drug

    Patient will apply daily 2 eye drops of GAL-101 at 5 minutes interval

  • PlaceboDrug

    Patient will apply daily 2 eye drops of Placebo at 5 minutes interval

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efficacy of GAL-101 ophthalmic solution in reducing the rate of change in GA lesion size.Time frame: From baseline to last on-treatment visit (48 up to 96 weeks)

Locations

24 sites in 8 countries. Site status is shown where the registry gives one.

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California · Recruiting

  • Bay Area Retina Associates

    Walnut Creek, California · Recruiting

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland · Suspended

  • Ophthalmological Center After S.V. Malayan

    Yerevan, Armenia · Recruiting

  • Centre Rétine Gallien

    Bordeaux, France · Recruiting

  • Hopital de La Croix-Rousse Service D'Ophtalmologie Groupement Hospitalier Nord Hospices Civils de Lyon

    Lyon, France · Recruiting

  • Centre Monticelli Paradis d'Ophtalmologie

    Marseille, France · Recruiting

  • Centre Ophtalmologique Odéon

    Paris, France · Recruiting

  • Centre médico-chirurgical de Touraine

    Tours, France · Recruiting

  • Akhali Mzera Limited

    Tbilisi, Georgia · Recruiting

  • Caucasus Medical Centre LLC

    Tbilisi, Georgia · Recruiting

  • Universitäts-Augenklinik Bonn

    Bonn, Germany · Recruiting

  • Universitätsklinikum Freiburg Klinik für Augenheilkunde

    Freiburg im Breisgau, Germany · Recruiting

  • Medizinische Hochschule Hannover Augenklinik

    Hanover, Germany · Recruiting

  • Dietrich Bonhoeffer Klinikum

    Neubrandenburg, Germany · Recruiting

  • Universitätsklinikum Tübingen, Department für Augenheilkunde.

    Tübingen, Germany · Recruiting

  • UNIVERSITÄTSKLINIKUM ULM Klinik für Augenheilkunde

    Ulm, Germany · Not yet recruiting

  • UPMC Kildare Hospital Prosperous Rd Clane, Kildare Ireland

    Kildare, Ireland · Recruiting

  • Institute of Eye Surgery (IOES Waterford)

    Waterford, Ireland · Recruiting

  • Hadassah Medical Center

    Jerusalem, Israel · Recruiting

  • Tel Aviv Medical Center

    Tel Aviv, Israel · Recruiting

  • Medical Retina & Imaging Unit, IRCCS MultiMedica, Ospedale San Giuseppe

    Milan, Milano, Italy · Recruiting

  • Unità di Oculistica, IRCCS Ospedale San Raffaele

    Milan, Milano, Italy · Recruiting

  • UOS Retina Medica, P.O. Britannico, IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia

    Roma, Roma, Italy · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.